VGI Health Technology (XNEC:VTL) Equity-to-Asset : 0.00 (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. VGI Health Technology's Total Stockholders Equity for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Total Assets for the quarter that ended in . 20 was A$0.00 Mil.

The historical rank and industry rank for VGI Health Technology's Equity-to-Asset or its related term are showing as below:

XNEC:VTL's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

VGI Health Technology Equity-to-Asset Historical Data

The historical data trend for VGI Health Technology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Equity-to-Asset Chart

VGI Health Technology Annual Data

Trend

Equity-to-Asset

VGI Health Technology Semi-Annual Data

Equity-to-Asset

Competitive Comparison of VGI Health Technology's Equity-to-Asset

For the Biotechnology subindustry, VGI Health Technology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Equity-to-Asset falls into.

VGI Health Technology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

VGI Health Technology's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as

Equity to Asset (A: . 20 )	=	Total Stockholders Equity	/	Total Assets
	=		/
	=

VGI Health Technology's Equity to Asset Ratio for the quarter that ended in . 20 is calculated as

Equity to Asset (Q: . 20 )	=	Total Stockholders Equity	/	Total Assets
	=		/
	=

VGI Health Technology (XNEC:VTL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

VGI Health Technology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines